| scholarly article | Q13442814 |
| P2093 | author name string | Dorina Kallogjeri | |
| Jay F Piccirillo | |||
| Murali M Chakinala | |||
| John S Schneider | |||
| Jake J Lee | |||
| Andrew M Peterson | |||
| P2860 | cites work | The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 |
| The use of US health insurance data for surveillance of rare disorders: hereditary hemorrhagic telangiectasia. | Q30632145 | ||
| Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action | Q33574011 | ||
| The clinical global impressions scale: applying a research tool in clinical practice | Q33894649 | ||
| Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). | Q33897059 | ||
| Prognostic importance of comorbidity in a hospital-based cancer registry | Q35783153 | ||
| Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. | Q36762112 | ||
| Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan | Q37360797 | ||
| Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT) | Q37602295 | ||
| Metabolism of ophthalmic timolol: new aspects of an old drug | Q37850837 | ||
| Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial | Q38387863 | ||
| The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. | Q38961412 | ||
| Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants | Q41959654 | ||
| Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. | Q42279034 | ||
| Optimization of Thermoreversible In Situ Nasal Gel of Timolol Maleate. | Q42753080 | ||
| An epistaxis severity score for hereditary hemorrhagic telangiectasia | Q48906632 | ||
| Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. | Q50511848 | ||
| Topical propranolol for infantile haemangiomas: A systematic review. | Q51736166 | ||
| Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis | Q64039712 | ||
| Decreases in ciliary beat frequency due to intranasal administration of propranolol | Q70405944 | ||
| Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia | Q82481983 | ||
| Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia | Q87030942 | ||
| Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial | Q92710408 | ||
| P577 | publication date | 2020-09-17 | |
| P1433 | published in | JAMA Otolaryngology–Head & Neck Surgery | Q4787304 |
| P1476 | title | Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial |
Search more.